Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus
Yazar
Gordon, Caroline
Dooley, Mary Anne
Enocsson, Helena
Wirestam, Lina
Dahle, Charlotte
Padyukov, Leonid
Jonsen, Andreas
Urowitz, Murray B.
Gladmane, Dafna D.
ROMERO-DIAZ, Juanita
BAE, Sang-Cheol
KALUNIAN, Kenneth C.
VAN VOLLENHOVEN, Ronald F.
RAMOS-CASALS, Manuel
KAMEN, Diane L.
JACOBSEN, Soren
Peschken, Christine A.
Askanase, Anca
STOLL, Thomas
Bruce, Ian N.
Wettero, Jonas
Sjowall, Christopher
Inanc, Murat
MANZI, Susan
Ramsey-Goldman, Rosalind
Nived, Ola
STEINSSON, Kristjan
ZOMA, Asad A.
RUIZ-IRASTORZA, Guillermo
Lim, S. Sam
Fortin, Paul R.
Sanchez-Guerrero, Jorge
Clarke, Ann E.
Bernatsky, Sasha
HANLY, John G.
WALLACE, Daniel J.
Isenberg, David A.
Rahman, Anisur
MERRILL, Joan T.
GINZLER, Ellen
ALARCON, Graciela S.
CHATHAM, W. Winn
Petri, Michelle
KHAMASHTA, Munther
ARANOW, Cynthia
MACKAY, Meggan
Üst veri
Tüm öğe kaydını gösterÖzet
Objective: The soluble urokinase plasminogen activator receptor (suPAR) has potential as a prognosis and severity biomarker in several inflammatory and infectious diseases. In a previous cross-sectional study, suPAR levels were shown to reflect damage accrual in cases of systemic lupus erythematosus (SLE). Herein, we evaluated suPAR as a predictor of future organ damage in recent-onset SLE.
Koleksiyonlar
- Makale [92796]